Performance of 99m Tc-sestamibi SPECT/CT for Characterizing Renal Masses: Combined Results from a Prospective Scan-and-Resect Trial and Clinical Experience

^99mTc-sestamibi SPECT/CT is a novel method to effectively risk-stratify indeterminate renal masses. As with any non-surgical method for renal mass characterization, there are potential false positives and false negatives, and those should be weighed carefully in shared decision-making with the patient to guide further evaluation and management.